Tags

Type your tag names separated by a space and hit enter

A randomized, double-masked, placebo-controlled clinical trial of multivitamin supplementation for age-related lens opacities. Clinical trial of nutritional supplements and age-related cataract report no. 3.
Ophthalmology. 2008 Apr; 115(4):599-607.e1.O

Abstract

OBJECTIVE

To evaluate the effect of a multivitamin/mineral supplement on development or progression of age-related lens opacities.

DESIGN

Randomized, double-masked, single center, placebo-controlled clinical trial.

PARTICIPANTS

One thousand twenty participants, 55 to 75 years old and with early or no cataract, were randomly assigned to a daily tablet of a multivitamin/mineral formulation or a placebo.

METHODS

Baseline and annual lens photographs were graded for severity of lens opacities according to a modification of the Age-Related Eye Disease Study system for classifying cataracts.

MAIN OUTCOME MEASURES

The primary outcome was a prespecified increase from baseline in nuclear, cortical, or posterior subcapsular cataract (PSC) opacity grades or cataract surgery. Secondary outcomes included an increase in type-specific opacity grades, cataract surgery, and visual acuity (VA) loss from baseline > or =15 letters.

RESULTS

Participants were observed for an average of 9.0+/-2.4 years. There was a decrease in total lens events in participants assigned to the multivitamin/mineral formulation compared with those assigned to the placebo (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.68-0.98; P = 0.03). Nuclear events were significantly less common (HR, 0.66; 95% CI, 0.50-0.88; P = 0.004) and PSC events significantly more common (HR, 2.00; 95% CI, 1.35-2.98; P<0.001) in participants taking the multivitamin/mineral formulation than in those assigned to the placebo. No statistically significant treatment effects were seen for cortical opacities, moderate VA loss, or cataract surgery.

CONCLUSIONS

Lens events were less common in participants who took the multivitamin/mineral formulation, but treatment had opposite effects on the development or progression of nuclear and PSC opacities, the 2 most visually important opacity subtypes.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

18387406

Citation

Clinical Trial of Nutritional Supplements and Age-Related Cataract Study Group, et al. "A Randomized, Double-masked, Placebo-controlled Clinical Trial of Multivitamin Supplementation for Age-related Lens Opacities. Clinical Trial of Nutritional Supplements and Age-related Cataract Report No. 3." Ophthalmology, vol. 115, no. 4, 2008, pp. 599-607.e1.
Clinical Trial of Nutritional Supplements and Age-Related Cataract Study Group, Maraini G, Williams SL, et al. A randomized, double-masked, placebo-controlled clinical trial of multivitamin supplementation for age-related lens opacities. Clinical trial of nutritional supplements and age-related cataract report no. 3. Ophthalmology. 2008;115(4):599-607.e1.
Maraini, G., Williams, S. L., Sperduto, R. D., Ferris, F., Milton, R. C., Clemons, T. E., Rosmini, F., & Ferrigno, L. (2008). A randomized, double-masked, placebo-controlled clinical trial of multivitamin supplementation for age-related lens opacities. Clinical trial of nutritional supplements and age-related cataract report no. 3. Ophthalmology, 115(4), 599-e1. https://doi.org/10.1016/j.ophtha.2008.01.005
Clinical Trial of Nutritional Supplements and Age-Related Cataract Study Group, et al. A Randomized, Double-masked, Placebo-controlled Clinical Trial of Multivitamin Supplementation for Age-related Lens Opacities. Clinical Trial of Nutritional Supplements and Age-related Cataract Report No. 3. Ophthalmology. 2008;115(4):599-607.e1. PubMed PMID: 18387406.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized, double-masked, placebo-controlled clinical trial of multivitamin supplementation for age-related lens opacities. Clinical trial of nutritional supplements and age-related cataract report no. 3. AU - ,, AU - Maraini,Giovanni, AU - Williams,Sally L, AU - Sperduto,Robert D, AU - Ferris,Frederick, AU - Milton,Roy C, AU - Clemons,Traci E, AU - Rosmini,Francesco, AU - Ferrigno,Luigina, PY - 2007/10/30/received PY - 2007/12/06/revised PY - 2008/01/04/accepted PY - 2008/4/5/pubmed PY - 2008/5/2/medline PY - 2008/4/5/entrez SP - 599 EP - 607.e1 JF - Ophthalmology JO - Ophthalmology VL - 115 IS - 4 N2 - OBJECTIVE: To evaluate the effect of a multivitamin/mineral supplement on development or progression of age-related lens opacities. DESIGN: Randomized, double-masked, single center, placebo-controlled clinical trial. PARTICIPANTS: One thousand twenty participants, 55 to 75 years old and with early or no cataract, were randomly assigned to a daily tablet of a multivitamin/mineral formulation or a placebo. METHODS: Baseline and annual lens photographs were graded for severity of lens opacities according to a modification of the Age-Related Eye Disease Study system for classifying cataracts. MAIN OUTCOME MEASURES: The primary outcome was a prespecified increase from baseline in nuclear, cortical, or posterior subcapsular cataract (PSC) opacity grades or cataract surgery. Secondary outcomes included an increase in type-specific opacity grades, cataract surgery, and visual acuity (VA) loss from baseline > or =15 letters. RESULTS: Participants were observed for an average of 9.0+/-2.4 years. There was a decrease in total lens events in participants assigned to the multivitamin/mineral formulation compared with those assigned to the placebo (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.68-0.98; P = 0.03). Nuclear events were significantly less common (HR, 0.66; 95% CI, 0.50-0.88; P = 0.004) and PSC events significantly more common (HR, 2.00; 95% CI, 1.35-2.98; P<0.001) in participants taking the multivitamin/mineral formulation than in those assigned to the placebo. No statistically significant treatment effects were seen for cortical opacities, moderate VA loss, or cataract surgery. CONCLUSIONS: Lens events were less common in participants who took the multivitamin/mineral formulation, but treatment had opposite effects on the development or progression of nuclear and PSC opacities, the 2 most visually important opacity subtypes. SN - 1549-4713 UR - https://www.unboundmedicine.com/medline/citation/18387406/A_randomized_double_masked_placebo_controlled_clinical_trial_of_multivitamin_supplementation_for_age_related_lens_opacities__Clinical_trial_of_nutritional_supplements_and_age_related_cataract_report_no__3_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(08)00010-9 DB - PRIME DP - Unbound Medicine ER -